Matches in SemOpenAlex for { <https://semopenalex.org/work/W3029786705> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W3029786705 endingPage "400" @default.
- W3029786705 startingPage "397" @default.
- W3029786705 abstract "Objective To explore the efficacy of ligustrazine combined with chemotherapy in patients with relapsed or refractory NHL and the relationships with P-gp expression. Methods 60 Patients were randomized into reversal agent group (ligustrazine + chemotherapy) and control group (chemotherapy) and the outcome was analysed. P- gp expression was analysed by flow cytometry. Subgroup analysis was conducted a ccording to P-gp expression. Results 56 patients could be evaluated. Progression -free survival (PFS) showed no statistical diference in two groups ( P = 0.065 1 ) ; reversal agent group had a higher overall response rate (ORR) than control group(P=0. 048).Subgroup analysis showed 41 patients had P-gp( +). The complete remission rate and complete remission uncertain rate of patients with P-gp( + ) in reversal agent group and control group were 33. 33% and 8. 70% , respectively, reversal agent group had a significant advantage ( P = 0. 048). Patients with P-gp( + ) in reversal agent group had a higher ORR than control group (61. 11% vs 26. 09% ,P =0.024). Kaplan-Meier survival curve and Log-rank test showed patients with P-gp( + ) in reversal agent group had longer PFS than control group (P =0.046 4). Blood pressure in a small number of patients received ligustrazine therapy decreased,and mitigated after reducing the dose. Conclusion Ligustrazine combined with chemotherapy can elevate response rate,prolong PFS with manageable toxicity and correlate to P-gp expression in relapsed or refractory NHLKey words: Lymphoma,non-hodgkin; Drug resistance; Ligustrazine; Drug therapy, combination" @default.
- W3029786705 created "2020-06-05" @default.
- W3029786705 creator A5080003280 @default.
- W3029786705 creator A5081206647 @default.
- W3029786705 date "2010-05-08" @default.
- W3029786705 modified "2023-09-23" @default.
- W3029786705 title "Study on ligustrazine combined with chemotherapy in patients with relapsed or refractory non-Hodgkin's lymphoma" @default.
- W3029786705 doi "https://doi.org/10.3760/cma.j.issn.1673-422x.2010.05.023" @default.
- W3029786705 hasPublicationYear "2010" @default.
- W3029786705 type Work @default.
- W3029786705 sameAs 3029786705 @default.
- W3029786705 citedByCount "0" @default.
- W3029786705 crossrefType "journal-article" @default.
- W3029786705 hasAuthorship W3029786705A5080003280 @default.
- W3029786705 hasAuthorship W3029786705A5081206647 @default.
- W3029786705 hasConcept C126322002 @default.
- W3029786705 hasConcept C142424586 @default.
- W3029786705 hasConcept C143998085 @default.
- W3029786705 hasConcept C168563851 @default.
- W3029786705 hasConcept C187960798 @default.
- W3029786705 hasConcept C2776694085 @default.
- W3029786705 hasConcept C2779338263 @default.
- W3029786705 hasConcept C2780035454 @default.
- W3029786705 hasConcept C29730261 @default.
- W3029786705 hasConcept C3018657049 @default.
- W3029786705 hasConcept C3019864225 @default.
- W3029786705 hasConcept C44249647 @default.
- W3029786705 hasConcept C71924100 @default.
- W3029786705 hasConcept C86803240 @default.
- W3029786705 hasConcept C87355193 @default.
- W3029786705 hasConcept C90924648 @default.
- W3029786705 hasConcept C98274493 @default.
- W3029786705 hasConceptScore W3029786705C126322002 @default.
- W3029786705 hasConceptScore W3029786705C142424586 @default.
- W3029786705 hasConceptScore W3029786705C143998085 @default.
- W3029786705 hasConceptScore W3029786705C168563851 @default.
- W3029786705 hasConceptScore W3029786705C187960798 @default.
- W3029786705 hasConceptScore W3029786705C2776694085 @default.
- W3029786705 hasConceptScore W3029786705C2779338263 @default.
- W3029786705 hasConceptScore W3029786705C2780035454 @default.
- W3029786705 hasConceptScore W3029786705C29730261 @default.
- W3029786705 hasConceptScore W3029786705C3018657049 @default.
- W3029786705 hasConceptScore W3029786705C3019864225 @default.
- W3029786705 hasConceptScore W3029786705C44249647 @default.
- W3029786705 hasConceptScore W3029786705C71924100 @default.
- W3029786705 hasConceptScore W3029786705C86803240 @default.
- W3029786705 hasConceptScore W3029786705C87355193 @default.
- W3029786705 hasConceptScore W3029786705C90924648 @default.
- W3029786705 hasConceptScore W3029786705C98274493 @default.
- W3029786705 hasIssue "05" @default.
- W3029786705 hasLocation W30297867051 @default.
- W3029786705 hasOpenAccess W3029786705 @default.
- W3029786705 hasPrimaryLocation W30297867051 @default.
- W3029786705 hasRelatedWork W1496927303 @default.
- W3029786705 hasRelatedWork W1968246132 @default.
- W3029786705 hasRelatedWork W2183352065 @default.
- W3029786705 hasRelatedWork W2273608743 @default.
- W3029786705 hasRelatedWork W2349850789 @default.
- W3029786705 hasRelatedWork W2357852444 @default.
- W3029786705 hasRelatedWork W2388764994 @default.
- W3029786705 hasRelatedWork W2391151401 @default.
- W3029786705 hasRelatedWork W2481718434 @default.
- W3029786705 hasRelatedWork W2550247846 @default.
- W3029786705 hasRelatedWork W2788920241 @default.
- W3029786705 hasRelatedWork W2980789655 @default.
- W3029786705 hasRelatedWork W3029146370 @default.
- W3029786705 hasRelatedWork W3029303210 @default.
- W3029786705 hasRelatedWork W3029827038 @default.
- W3029786705 hasRelatedWork W3030683423 @default.
- W3029786705 hasRelatedWork W3031161616 @default.
- W3029786705 hasRelatedWork W3032054363 @default.
- W3029786705 hasRelatedWork W3095664476 @default.
- W3029786705 hasRelatedWork W656190786 @default.
- W3029786705 hasVolume "37" @default.
- W3029786705 isParatext "false" @default.
- W3029786705 isRetracted "false" @default.
- W3029786705 magId "3029786705" @default.
- W3029786705 workType "article" @default.